These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 22135116)

  • 1. Economic model of a birth cohort screening program for hepatitis C virus.
    McGarry LJ; Pawar VS; Panchmatia HR; Rubin JL; Davis GL; Younossi ZM; Capretta JC; O'Grady MJ; Weinstein MC
    Hepatology; 2012 May; 55(5):1344-55. PubMed ID: 22135116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
    Rein DB; Smith BD; Wittenborn JS; Lesesne SB; Wagner LD; Roblin DW; Patel N; Ward JW; Weinbaum CM
    Ann Intern Med; 2012 Feb; 156(4):263-70. PubMed ID: 22056542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
    McEwan P; Ward T; Yuan Y; Kim R; L'italien G
    Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
    Cammà C; Petta S; Cabibbo G; Ruggeri M; Enea M; Bruno R; Capursi V; Gasbarrini A; Alberti A; Craxì A;
    J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic assessment of an anti-HCV screening program in Italy.
    Ruggeri M; Coretti S; Gasbarrini A; Cicchetti A
    Value Health; 2013; 16(6):965-72. PubMed ID: 24041346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England.
    Williams J; Miners A; Harris R; Mandal S; Simmons R; Ireland G; Hickman M; Gore C; Vickerman P
    Value Health; 2019 Nov; 22(11):1248-1256. PubMed ID: 31708061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and population outcomes of general population screening for hepatitis C.
    Coffin PO; Scott JD; Golden MR; Sullivan SD
    Clin Infect Dis; 2012 May; 54(9):1259-71. PubMed ID: 22412061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of screening immigrants for hepatitis B.
    Wong WW; Woo G; Jenny Heathcote E; Krahn M
    Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of expanded newborn screening in Texas.
    Tiwana SK; Rascati KL; Park H
    Value Health; 2012; 15(5):613-21. PubMed ID: 22867769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
    He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
    Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
    Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
    Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evidence of high prevalence of Hepatitis C virus in Faisalabad, Pakistan.
    Ahmad N; Asgher M; Shafique M; Qureshi JA
    Saudi Med J; 2007 Mar; 28(3):390-5. PubMed ID: 17334466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
    Kim DD; Hutton DW; Raouf AA; Salama M; Hablas A; Seifeldin IA; Soliman AS
    Glob Public Health; 2015; 10(3):296-317. PubMed ID: 25469976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.
    Plunkett BA; Grobman WA
    Am J Obstet Gynecol; 2005 Apr; 192(4):1153-61. PubMed ID: 15846195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.
    Younossi ZM; Tanaka A; Eguchi Y; Henry L; Beckerman R; Mizokami M
    J Viral Hepat; 2018 Aug; 25(8):945-951. PubMed ID: 29478258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
    BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland.
    Bruggmann P; Negro F; Bihl F; Blach S; Lavanchy D; Müllhaupt B; Razavi H; Semela D
    Swiss Med Wkly; 2015; 145():w14221. PubMed ID: 26715488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection.
    Deuffic-Burban S; Abiteboul D; Lot F; Branger M; Bouvet E; Yazdanpanah Y
    Gut; 2009 Jan; 58(1):105-10. PubMed ID: 18824553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.